Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.39 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.32 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.31 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL753567 | 0.98 | TSHR (0.41) | TSHRACHETDP1CYP3A4TRPA1 | |
| Water SCHEMBL28584406 | 0.95 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL154108 | 0.91 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL31150435 | 0.91 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL3327763 | 0.89 | TSHR (0.38) | TSHRACHETDP1CYP3A4TRPA1 | |
| SCHEMBL752673 | 0.88 | TSHR (0.41) | TSHRACHETDP1CYP3A4TRPA1 | |
| Water SCHEMBL5196978 | 0.86 | TSHR (0.39) | TSHRACHETDP1CYP3A4TRPA1 | |
| Hydrochloric Acid SCHEMBL4369366 | 0.86 | ACHE (0.43) | TSHRACHETDP1CYP3A4GAA | |
| SCHEMBL752807 | 0.83 | ACHE (0.45) | TSHRACHETDP1CYP3A4GAA | |
| Acetic Acid SCHEMBL5196852 | 0.82 | GAA (0.40) | TDP1CYP3A4TRPA1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046767-B1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVENCE TECHNOLOGIES (FR) | 2015-04-22 | — | — | EP | claimed |
| US-8765942-B2 | Process for preparing diaminophenothiazinium compounds | PROVENCE TECHNOLOGIES (FR) | 2014-07-01 | — | — | US | claimed |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2009-11-26 | — | — | US | claimed |
| US-12442029-B2 | Method and system for imaging a blood sample | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2025-10-14 | — | — | US | disclosed |
| US-20220390734-A1 | METHOD AND SYSTEM FOR IMAGING A BLOOD SAMPLE | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2022-12-08 | — | — | US | disclosed |
| US-11434515-B2 | Method and system for imaging a blood sample | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2022-09-06 | — | — | US | disclosed |
| CN-109342155-B | Method, kit and system for imaging a blood sample | 思迪赛特诊断有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-20190002950-A1 | METHOD AND SYSTEM FOR IMAGING A BLOOD SAMPLE | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2019-01-03 | — | — | US | disclosed |
| US-10093957-B2 | Method, kit and system for imaging a blood sample | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2018-10-09 | — | — | US | disclosed |
| US-20180287166-A1 | ELECTROCHEMICAL REACTOR BLOCK | Universite Grenoble-Alpes (FR) | 2018-10-04 | — | — | US | disclosed |
| US-10087153-B2 | Method of preparing diaminophenothiazinium | Curadel, LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-9329129-B2 | Method, kit and system for imaging a blood sample | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2016-05-03 | — | — | US | disclosed |
| US-9227945-B2 | Process for preparing diaminophenothiazinium compounds | PROVENCE TECHNOLOGIES (FR) | 2016-01-05 | — | — | US | disclosed |
| US-20150316477-A1 | METHOD, KIT AND SYSTEM FOR IMAGING A BLOOD SAMPLE | S.D. SIGHT DIAGNOSTICS LTD. (IL) | 2015-11-05 | — | — | US | disclosed |
| WO-2015001553-A1 | A METHOD, KIT AND SYSTEM FOR IMAGING A BLOOD SAMPLE | SIGHT DIAGNOSTICS LTD. (IL) | 2015-01-08 | — | — | WO | disclosed |
| US-8815850-B2 | Process for preparing diaminophenothiazinium compounds | PROVENCE TECHNOLOGIES (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20140235854-A1 | Process for Preparing Diaminophenothiazinium Compounds | PROVENCE TECHNOLOGIES (FR) | 2014-08-21 | — | — | US | disclosed |
| US-8765942-B2 | Process for preparing diaminophenothiazinium compounds | PROVENCE TECHNOLOGIES (FR) | 2014-07-01 | — | — | US | disclosed |
| US-20130005713-A1 | Process for Preparing Diaminophenothiazinium Compounds | PROVENCE TECHNOLOGIES (FR) | 2013-01-03 | — | — | US | disclosed |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | PROVEPHARM LIFE SOLUTIONS (FR) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10087153-B2 | Method of preparing diaminophenothiazinium | NEFM, DDT, DUS2 | ACHE 1530/4885GAA 3118/4885CA2 4017/4885 |
| US-20090291943-A1 | PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS | DCPS, QDPR, DNPEP | ACHE 2384/4885GAA 380/4885CA2 2381/4885 |
| US-20140235854-A1 | Process for Preparing Diaminophenothiazinium Compounds | DRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C5 | ACHE 2866/4885GAA 4034/4885CA2 3958/4885 |
| US-20130005713-A1 | Process for Preparing Diaminophenothiazinium Compounds | DCPS, QDPR, DNPEP | ACHE 2737/4885GAA 421/4885CA2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.